Source: Organon
Organon, a women’s health company, set objectives for increasing access to healthcare last summer in its inaugural environmental, social, and governance report. By 2030, the pharmaceutical company committed to attempting to avoid 120 million unplanned births and provide 100 million girls and women in low- and middle-income nations inexpensive access to contraception.
In order to assist it meet its goals and contribute to the UN Sustainable Development Goals, Organon has now established a memorandum of understanding (MOU) with CAF – Development Bank of Latin America.
In accordance with the MOU’s conditions, the newly formed partners want to work together on the “design, structure, and implementation of sustainable programmes that promote and improve equity, health, and autonomy of girls and women in Latin America and the Caribbean.” The objective is to “advance progress in women’s health by mobilizing capital towards initiatives that might not otherwise receive adequate support.”
Organon emphasized that expanding access to sexual and reproductive health information and services is an area that might need more investment. The MOU demonstrates Organon’s support for outcomes-based finance, a strategy that associates development funds with previously agreed-upon and independently verifiable results. Executive president of CAF Sergio Diaz-Granados talked about the potential outcomes of the money.
“This agreement with Organon will help us to join forces in order to break with the structural barriers that keep limiting the access of women to health, financial and non-financial services.”
– Diaz-Granados Executive President of CAF
Organon’s partnership with CAF aims to enhance the well-being, equality, and independence of females in Latin America and the Caribbean. This collaboration will focus on prioritizing and improving the health of women, while also providing them with the necessary resources and assistance to lead productive and satisfying lives, thereby contributing to economic progress. The pharmaceutical company is attempting to demonstrate to countries how investing in health helps their citizens and economies by using data. Mexico, Colombia, Ecuador, Peru, Panama, Thailand, Kenya, and South Africa all have programmes functioning.
